CalciMedica Announces $21 Million Series D Financing
March 11, 2021 16:05 ET | CalciMedica
Round led by Quark Venture LP and Global Health Sciences (GHS) FundFunds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe and critical COVID-19...
CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress
February 02, 2021 08:00 ET | CalciMedica
D-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA...
CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
December 17, 2020 08:00 ET | CalciMedica
Blinded placebo-controlled trial is expected to enroll more than 100 patients at U.S. clinical sites by end of DecemberThe Company expects to complete enrollment of the trial by the end of Q1 2021 LA...
CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
November 13, 2020 08:00 ET | CalciMedica
First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a complication of strokeCRAC channel inhibitors represent an important future potential...
CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer
November 05, 2020 08:00 ET | CalciMedica
Mr. Geffken brings more than three decades of financial experience to CalciMedica; involved in 12 IPO filings since 2013 LA JOLLA, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc....
CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia
August 18, 2020 08:00 ET | CalciMedica
Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of...
CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies
July 21, 2020 08:00 ET | CalciMedica; EpiPharma LLC
Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug...
CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia
July 16, 2020 08:00 ET | CalciMedica
Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care aloneThe percentage of patients requiring invasive mechanical...
UPDATE - CalciMedica Appoints Robert N. Wilson as Co-Chairman of the Board of Directors and Eric W. Roberts as Vice Chairman
June 02, 2020 15:57 ET | CalciMedica
Robert N. Wilson was Former Johnson & Johnson Vice ChairmanBoard Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and Finance Committee of the Board LA...
CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
May 28, 2020 08:00 ET | CalciMedica
Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone LA JOLLA, Calif., May 28, 2020 (GLOBE...